Jae Ri Kim
Seoul National University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jae Ri Kim.
Journal of Hepato-biliary-pancreatic Sciences | 2015
Jae Ri Kim; Jin-Young Jang; Mee Joo Kang; Taesung Park; Seung Yeoun Lee; Woohyun Jung; Jihoon Chang; Y.C. Shin; Young-Min Han; Sun-Whe Kim
Little is known about the prognostic significance of serum carbohydrate antigen (CA) 19‐9 and carcinoembryonic antigen (CEA) concentrations for predicting malignancy in patients with intraductal papillary mucinous neoplasm (IPMN) of pancreas.
Journal of The Korean Surgical Society | 2017
Hyeong Seok Kim; Jin-Young Jang; Young-Min Han; Kyoung Bun Lee; Ijin Joo; Doo-Ho Lee; Jae Ri Kim; Hongbeom Kim; Wooil Kwon; Sun-Whe Kim
Purpose Neoadjuvant treatment may provide improved survival outcomes for patients with borderline resectable pancreatic cancer (BRPC). The purpose of this study is to evaluate the clinical outcomes of neoadjuvant treatment and to identify prognostic factors. Methods Forty patients who met the National Comprehensive Cancer Network definition of BRPC and received neoadjuvant treatment followed by surgery between 2007 and 2015 were evaluated. Prospectively collected clinicopathological outcomes were analyzed retrospectively. Results The mean age was 61.7 years and the male-to-female ratio was 1.8:1. Twenty-six, 3, and 11 patients received gemcitabine-based chemotherapy, 5-fluorouracil, and FOLFIRINOX, respectively. The 2-year survival rate (2YSR) was 36.6% and the median overall survival (OS) was 20 months. Of the 40 patients, 34 patients underwent resection and the 2YSR was 41.2% while the 2YSR of patients who did not undergo resection was 16.7% (P = 0.011). The 2YSR was significantly higher in patients who had partial response compared to stable disease (60.6% vs. 24.3%, P = 0.038), in patients who did than did not show a CA 19-9 response after neoadjuvant treatment (40.5% vs. 0%, P = 0.039) and in patients who did than did not receive radiotherapy (50.8% vs. 25.3%, P = 0.036). Five patients had local recurrence and 17 patients had systemic recurrence with a median disease specific survival of 15 months. Conclusion Neoadjuvant treatment followed by resection is effective for BRPC. Pancreatectomy and neoadjuvant treatment response may affect survival. Effective systemic therapy is needed to improve long-term survival since systemic metastasis accounts for a high proportion of recurrence.
Medicine | 2016
Jin-Young Jang; Jin Seok Heo; Young-Min Han; Jihoon Chang; Jae Ri Kim; Hongbeom Kim; Wooil Kwon; Sun-Whe Kim; Seong-Ho Choi; Dong Wook Choi; Kyoungbun Lee; Kee-Taek Jang; Sung-Sik Han; Sang-Jae Park
AbstractLaparoscopic surgery has been widely accepted as a feasible and safe treatment modality in many cancers of the gastrointestinal tract. However, most guidelines on gallbladder cancer (GBC) regard laparoscopic surgery as a contraindication, even for early GBC. This study aims to evaluate and compare recent surgical outcomes of laparoscopic and open surgery for T1(a,b) GBC and to determine the optimal surgical strategy for T1 GBC.The study enrolled 197 patients with histopathologically proven T1 GBC and no history of other cancers who underwent surgery from 2000 to 2014 at 3 major tertiary referral hospitals with specialized biliary-pancreas pathologists and optimal pathologic handling protocols. Median follow-up was 56 months. The effects of depth of invasion and type of surgery on disease-specific survival and recurrence patterns were investigated.Of the 197 patients, 116 (58.9%) underwent simple cholecystectomy, including 31 (15.7%) who underwent open cholecystectomy and 85 (43.1%) laparoscopic cholecystectomy. The remaining 81 (41.1%) patients underwent extended cholecystectomy. Five-year disease-specific survival rates were similar in patients who underwent simple and extended cholecystectomy (96.7% vs 100%, P = 0.483), as well as being similar in patients in the simple cholecystectomy group who underwent open and laparoscopic cholecystectomy (100% vs 97.6%, P = 0.543). Type of surgery had no effect on recurrence patterns.Laparoscopic cholecystectomy for T1 gallbladder cancer can provide similar survival outcomes compared to open surgery. Considering less blood loss and shorter hospital stay with better cosmetic outcome, laparoscopic cholecystectomy can be justified as a standard treatment for T1b as well as T1a gallbladder cancer when done by well-experienced surgeons based on exact pathologic diagnosis.
International Journal of Medical Robotics and Computer Assisted Surgery | 2017
Hongbeom Kim; Jae Ri Kim; Young-Min Han; Wooil Kwon; Sun-Whe Kim; Jin-Young Jang
Laparoscopic surgery and robotic surgery have their own merits and demerits. The aim of this study was to evaluate early experiences of hybrid pancreaticoduodenectomy (PD) and to identify the learning curve of robotic surgery.
Journal of Hepato-biliary-pancreatic Sciences | 2018
Hyeong Seok Kim; Young-Min Han; Jae Seung Kang; Hongbeom Kim; Jae Ri Kim; Wooil Koon; Sun-Whe Kim; Jin-Young Jang
Robot surgery is a new method that maintains advantages and overcomes disadvantages of conventional methods, even in pancreatic surgery. This study aimed to evaluate safety and benefits of robot‐assisted minimally invasive pancreaticoduodenectomy (robot PD).
Journal of Hepato-biliary-pancreatic Sciences | 2017
Jin He; Jae Ri Kim; Seung Yeoun Lee; Jinseok Oh; Taesung Park; Mee Joo Kang; Wooil Kwon; Hongbeom Kim; Sun Whe Kim; John L. Cameron; Christopher L. Wolfgang; J.-Y. Jang
We built a multinational retrospective database of patients with ampulla of Vater cancer to develop a reliable new staging system.
Medicine | 2016
Hongbeom Kim; Jin-Young Jang; Donghee Son; Seungyeoun Lee; Young-Min Han; Yong Chan Shin; Jae Ri Kim; Wooil Kwon; Sun-Whe Kim
AbstractStapling is a popular method for stump closure in distal pancreatectomy (DP). However, research on which cartridges are suitable for different pancreatic thickness is lacking. To identify the optimal stapler cartridge choice in DP according to pancreatic thickness.From November 2011 to April 2015, data were prospectively collected from 217 consecutive patients who underwent DP with 3-layer endoscopic staple closure in Seoul National University Hospital, Korea. Postoperative pancreatic fistula (POPF) was graded according to International Study Group on Pancreatic Fistula definitions. Staplers were grouped based on closed length (CL) (Group I: CL ⩽ 1.5 mm, II: 1.5 mm < CL < 2 mm, III: CL ≥ 2 mm). Compression ratio (CR) was defined as pancreas thickness/CL. Distribution of pancreatic thickness was used to find the cut-off point of thickness which predicts POPF according to stapler groups.POPF developed in 130 (59.9%) patients (Grade A; n = 86 [66.1%], B; n = 44 [33.8%]). The numbers in each stapler group were 46, 101, and 70, respectively. Mean thickness was higher in POPF cases (15.2 mm vs 13.5 mm, P = 0.002). High body mass index (P = 0.003), thick pancreas (P = 0.011), and high CR (P = 0.024) were independent risk factors for POPF in multivariate analysis. Pancreatic thickness was grouped into <12 mm, 12 to 17 mm, and >17 mm. With pancreatic thickness <12 mm, the POPF rate was lowest with Group II (I: 50%, II: 27.6%, III: 69.2%, P = 0.035).The optimal stapler cartridges with pancreatic thickness <12 mm were those in Group II (Gold, CL: 1.8 mm). There was no suitable cartridge for thicker pancreases. Further studies are necessary to reduce POPF in thick pancreases.
Journal of Korean Medical Science | 2018
Jae Ri Kim; Kyoungbun Lee; Wooil Kwon; Eun Jung Kim; Sun-Whe Kim; Jin-Young Jang
Background Intraductal papillary neoplasm of the bile duct (IPNB) is a recently defined entity and its clinical characteristics and classifications have yet to be established. We aimed to clarify the clinical features of IPNB and determine the optimal morphological classification criteria. Methods From 2003 to 2016, 112 patients with IPNB who underwent surgery were included in the analysis. After pathologic reexamination by a specialized biliary-pancreas pathologist, previously suggested morphological and anatomical classifications were compared using the clinicopathologic characteristics of IPNB. Results In terms of histologic subtypes, most patients had the intestinal type (n = 53; 48.6%) or pancreatobiliary type (n = 33; 30.3%). The simple “modified anatomical classification” showed that extrahepatic IPNB comprised more of the intestinal type and tended to be removed by bile duct resection or pancreatoduodenectomy. Intrahepatic IPNB had an equally high proportion of intestinal and pancreatobiliary types and tended to be removed by hepatobiliary resection. Morphologic classifications and histologic subtypes had no effect on survival, whereas a positive resection margin (75.9% vs. 25.7%; P = 0.004) and lymph node metastasis (75.3% vs. 30.0%; P = 0.091) were associated with a poor five-year overall survival rate. In the multivariate analysis, a positive resection margin and perineural invasion were important risk factors for survival. Conclusion IPNB showed better long-term outcomes after optimal surgical resection. The “modified anatomical classification” is simple and intuitive and can help to select a treatment strategy and establish the proper scope of the operation.
Journal of Hepato-biliary-pancreatic Sciences | 2018
Hongeun Lee; Young-Min Han; Jae Ri Kim; Wooil Kwon; Sun-Whe Kim; Jin-Young Jang
The use of preoperative biliary drainage (PBD) for managing patients with periampullary cancer awaiting surgery remains controversial. The impact of PBD status and type on surgical outcomes has not been established, leading to a lack of consensus. We aimed to evaluate the impact of PBD on short‐term surgical outcomes in curatively resected periampullary cancer.
Journal of Hepato-biliary-pancreatic Sciences | 2018
Jae Seung Kang; Seungyeoun Lee; Donghee Son; Young-Min Han; Kyung Bun Lee; Jae Ri Kim; Wooil Kwon; Sun-Whe Kim; Jin-Young Jang
The new 8th American Joint Committee on Cancer (AJCC) staging has recently been released and there are major changes in distal bile duct (DBD) cancer staging. However, clinical validation is needed before the changes can be widely implemented.